Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Indolent lymphomas: pushing the pace with novel agents

Caron A. Jacobson

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 279–286.

https://doi.org/10.1182/hematology.2019000032

Published: 2019

Journal Articles

Relapsed disease and aspects of undetectable MRD and treatment discontinuation

Barbara Eichhorst, Moritz Fürstenau, Michael Hallek

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 482–489.

https://doi.org/10.1182/hematology.2019000070

Published: 2019

Journal Articles

Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials

Jennifer A. Woyach

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 476–481.

https://doi.org/10.1182/hematology.2019001321

Published: 2019

Journal Articles

Molecular profiling and management of mantle cell lymphoma

Jia Ruan

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 30–40.

https://doi.org/10.1182/hematology.2019000011

Published: 2019

Journal Articles

Clonal dynamics in chronic lymphocytic leukemia

Catherine Gutierrez, Catherine J. Wu

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 466–475.

https://doi.org/10.1182/hematology.2019000367

Published: 2019

Journal Articles

Selecting Frontline Therapy for CLL in 2018

Nitin Jain

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 242–247.

https://doi.org/10.1182/asheducation-2018.1.242

Published: 2018

Journal Articles

Relapsed CLL: sequencing, combinations, and novel agents

Jennifer R. Brown

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 248–255.

https://doi.org/10.1182/asheducation-2018.1.248

Published: 2018

Journal Articles

The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment

Gianluca Gaidano, Davide Rossi

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 329–337.

https://doi.org/10.1182/asheducation-2017.1.329

Published: 2017

Journal Articles

How should we sequence and combine novel therapies in CLL?

Matthew S. Davids

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 346–353.

https://doi.org/10.1182/asheducation-2017.1.346

Published: 2017

Journal Articles

Safety profiles of novel agent therapies in CLL

Inhye E. Ahn, Matthew S. Davids

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 354–357.

https://doi.org/10.1182/asheducation-2017.1.354

Published: 2017

Journal Articles

Sequencing of chronic lymphocytic leukemia therapies

Jacqueline C. Barrientos

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 128–136.

https://doi.org/10.1182/asheducation-2016.1.128

Published: 2016

Journal Articles

Novel agents in chronic lymphocytic leukemia

Nicole Lamanna, Susan O’Brien

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 137–145.

https://doi.org/10.1182/asheducation-2016.1.137

Published: 2016

Journal Articles

First-line therapy for young patients with CLL

Nitin Jain, Susan O’Brien

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 146–148.

https://doi.org/10.1182/asheducation-2016.1.146

Published: 2016

Journal Articles

Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly

Marco Ruella, Pierre Soubeyran

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 432–436.

https://doi.org/10.1182/asheducation-2016.1.432

Published: 2016

Journal Articles

Patterns of resistance to B cell–receptor pathway antagonists in chronic lymphocytic leukemia and strategies for management

Jennifer A. Woyach

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 355–360.

https://doi.org/10.1182/asheducation-2015.1.355

Published: 2015

Journal Articles

Prognostic markers and standard management of chronic lymphocytic leukemia

Stephan Stilgenbauer

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 368–377.

https://doi.org/10.1182/asheducation-2015.1.368

Published: 2015

Journal Articles

Management of prolymphocytic leukemia

Claire Dearden

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 361–367.

https://doi.org/10.1182/asheducation-2015.1.361

Published: 2015

Journal Articles

B-cell receptor pathway modulators in NHL

Kristie A. Blum

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 82–91.

https://doi.org/10.1182/asheducation-2015.1.82

Published: 2015

Journal Articles

BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma

Adrian Wiestner

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 125–134.

https://doi.org/10.1182/asheducation-2014.1.125

Published: 2014

Journal Articles

Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies

Michael Hallek

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 138–150.

https://doi.org/10.1182/asheducation-2013.1.138

Published: 2013

NARROW

Indolent lymphomas: pushing the pace with novel agents

Relapsed disease and aspects of undetectable MRD and treatment discontinuation

Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials

Molecular profiling and management of mantle cell lymphoma

Clonal dynamics in chronic lymphocytic leukemia

Selecting Frontline Therapy for CLL in 2018

Relapsed CLL: sequencing, combinations, and novel agents

The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment

How should we sequence and combine novel therapies in CLL?

Safety profiles of novel agent therapies in CLL

Sequencing of chronic lymphocytic leukemia therapies

Novel agents in chronic lymphocytic leukemia

First-line therapy for young patients with CLL

Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly

Patterns of resistance to B cell–receptor pathway antagonists in chronic lymphocytic leukemia and strategies for management

Prognostic markers and standard management of chronic lymphocytic leukemia

Management of prolymphocytic leukemia

B-cell receptor pathway modulators in NHL

BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma

Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only